Scientists test First-Ever vaccine to stop hereditary cancer before it starts
NCT ID NCT07163403
Summary
This is a first-in-human study testing a personalized vaccine called DC-DELAY, designed to prevent cancer in people with Lynch syndrome—a genetic condition that greatly increases cancer risk. The trial will enroll 20 participants to primarily check if the vaccine is safe and if it triggers a protective immune response. Researchers will also monitor participants for several years to see if the vaccine reduces the development of precancerous growths and cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYNCH SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Laura Burunat
RECRUITINGBarcelona, Barcelona, 08036, Spain
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.